Key Points Carfilzomib is associated with reversible cardiotoxicity in 12% of consecutive myeloma patients. Transient renal toxicity is common, but carfilzomib may improve renal function in myeloma-related renal impairment.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: